NY Times article on a Moral Crisis for Americas doctors - the corporatization of Medicine leverages finances/incomes against physican values and practice preferences. Rheum Dr. Diana Girnita presents the Direct Medical Care option for MD autonomy https://t.co/TySD8l6I94 https://t.co/ZNTx7VVRfg

EULAR 2023 Notes from Milan https://t.co/cdmkiJmQrz https://t.co/w6UV85bFQ1

Watch: A Real Boost for Shingrix with JAKi Dr. David Liew discusses OP0225 presented at EULAR 2023 in Milan, Italy. https://t.co/Xgt85l6WgQ https://t.co/jPcA2GSFdm

ACR Concerned with MedPAC’s Cutting Part B Reimbursement ACR took issue with the orgs reco to Congress to keep a 6% add-on payment for the lowest-cost drugs, reduce the add-on payment for mid-to-high-level drugs, and add a payment cap for the $$$ drugs. https://t.co/IwZO88QThb https://t.co/GHjDwbHCCo

FAAH and FAAH-OUT - genes involved in pain perception; could these be the target of future therapies? Interesting article in FORBES bout role of FAAH and FAAH-OUT in pain. https://t.co/8FNvkVZy5R https://t.co/8Ldywt2wvq

Higher Genetic Loads Linked to Worse Systemic Lupus A study of a large SLE cohort shows by genomic analysis, that higher wGRS is associated with earlier SLE onset, higher anti–Sm antibody positivity, lupus nephritis and more diverse lupus manifestations. https://t.co/L8ZZEgcfNM https://t.co/elwDtDuSjP

WATCH: Update on CAR T-Cell Therapy in SLE & Autoimmune Diseases Dr. Peter Nash reporting from EULAR 2023 in Milan, Italy. https://t.co/EpsPtwtJJt https://t.co/QxH8Pff6RS

275 early RA pts and after 2 years, 32% reported unacceptable pain (UP). Predictors of UP best seen at 3 mos FUV (not baseline) and included #Tender Jts (not swollen), overall pain, patient global assessment, and HAQ. https://t.co/Zlv3919Ucz https://t.co/1K1zPvhUYi

EULAR Offers Tips on Psoriasis Progression to PsA Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" from the EULAR. https://t.co/eFsWJBmzCR https://t.co/slq58tWJG6

Biosimilars Match Biologic Originators in RA A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA. https://t.co/EO22ThFL5C https://t.co/wlK0e2Cg5l

BIOSIMILARS (93 in EU, 40 in US) are approaching a tipping point with 8 new adalimumab biosimilars in 2023. Humira sales are down ~26% in 2023. Biosimilar sales expected - $129 billion in next 5 yrs, with estimated savings of $181 billion https://t.co/HMOYaSaIBQ https://t.co/6jOujr4JXQ

Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/AP89MAIlJM https://t.co/YpfWFCLF1z